Related Experiment Video
Updated: May 28, 2026
08:46
Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
Genetic variation and pharmacogenomics: concepts, facts, and challenges
Margret R Hoehe1, Thomas Kroslak
1Genetic Variation Program, Department of Vertebrate Genomics, Max Planck Institute for Molecular Genetics, Berlin, Germany.
Dialogues in Clinical Neuroscience
|October 29, 2011
Summary
Analyzing genetic variation in candidate genes is crucial for pharmacogenomics and personalized medicine. Understanding gene sequence and haplotype diversity is essential for linking genetic variants to drug responses and phenotypes.
Area of Science:
- Genomics
- Pharmacogenomics
- Human Genetics
Background:
- Candidate gene analysis is central to pharmacogenomics.
- Understanding genetic variation impacts disease gene identification and drug response.
- Historical approaches to candidate gene analysis have evolved with genome research.
Purpose of the Study:
- To distinguish different approaches to candidate gene analysis.
- To highlight the importance of haplotype-based approaches for high-resolution genetic variation analysis.
- To summarize current data on genetic variation in candidate genes.
Main Methods:
- Review of historical and recent approaches to candidate gene analysis.
- Focus on DNA sequence-level analysis.
- Emphasis on haplotype determination and analysis.
Main Results:
- Genetic variation analysis has advanced to DNA sequence resolution.
- Haplotype-based approaches are now recognized as essential.
- Data reveal abundant gene sequence and haplotype diversity, with numerous gene forms existing.
- Significant challenges exist in analyzing genotype-phenotype relationships.
Conclusions:
- In-depth knowledge of candidate gene variation is a prerequisite for future pharmacogenomics.
- Naturally occurring genetic variation has clear implications for personalized medicine.
- Future drug target identification, clinical trial optimization, and therapy development must leverage this knowledge.
Related Concept Videos
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...